ProKidney Corp. (PROK) Investor Relations Documents

ProKidney Corp. (PROK) investor relations documents from the company's IR site: 3 presentations, 26 press releases; latest deck 2026-05-14. Read in-app with summaries. First-party data.

ProKidney Corporate Presentation May 2026: ProKidney is developing rilparencel, an autologous cell therapy for advanced CKD, with pivotal Phase 3 PROACT 1 topline data expected in Q2 2027.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-10Press releaseProKidney Reports Second Quarter 2026 Financial Results and Business Highlights
2026-06-02Press releaseProKidney Appoints Kenneth Locke as Chief Technical Officer
2026-05-15Press releaseProKidney Reports First Quarter 2026 Financial Results and Business Highlights
2026-05-14PresentationProKidney Corporate Presentation May 2026
2026-03-25Press releaseProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer
2026-03-18Press releaseProKidney Reports Full Year 2025 Financial Results and Business Highlights
2026-01-14PresentationJ.P. Morgan Presentation 2026
2026-01-06Press releaseProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference
2025-11-10Press releaseProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates
2025-11-06Press releaseProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Ki
2025-10-29Press releaseProKidney to Participate in Two Upcoming Conferences: Guggenheim Healthcare Innovation Conference and the Jefferies Glob
2025-10-20Press releaseProKidney Announces Two Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2025
2025-08-27Press releaseProKidney to Participate in Two Upcoming Conferences: the Citi Biopharma Back to School Conference and the Morgan Stanle
2025-07-15Press releaseProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel
2025-07-08Press releaseProKidney Reports Statistically and Clinically Significant Topline Results for the Phase 2 REGEN-007 Trial Evaluating Ri
2025-03-17Press releaseEarnings Press Release
2025-02-08PresentationJ.P. Morgan Presentation 2025
2024-11-26Press releaseProKidney to Participate in Two Upcoming Conferences: Evercore HealthCONx Conference and the Citi Global Healthcare Conf
2024-11-12Press releaseEarnings Press Release
2024-11-05Press releaseProKidney to Participate in the Guggenheim Inaugural Healthcare Innovation Conference and the Jefferies London Healthcar
2024-08-09Press releaseEarnings Press Release
2024-05-10Press releaseEarnings Press Release
2024-03-21Press releaseEarnings Press Release
2023-08-10Press releaseEarnings Press Release
2023-05-26Proxy statement2023 Annual Shareholder General Meeting Presentation
2023-05-11Press releaseEarnings Press Release
2023-03-28Press releaseEarnings Press Release
2022-11-14Press releaseEarnings Press Release
2022-08-11Press releaseEarnings Press Release
Press releaseProKidney to Participate in Jefferies Biotech on the Bay Summit

PROK overview · PROK earnings · PROK financials · PROK KPIs · PROK ownership · PROK peers · PROK filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.